Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246467 · ClinicalTrials.gov registry record · Phase 1
One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)
A Phase 1 study, sponsored by PharmAthene UK Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 123
- Enrollment target
NCT00246467 is a Phase 1 study that has completed, run by PharmAthene UK Limited. The registered enrollment target is 123 participants.
The verdict
NCT00246467, a Phase 1 study, has completed, sponsored by PharmAthene UK Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 123 participants
- Enrollment target
Study Summary
One hundred and five subjects will be recruited into three groups. Each subject will receive two doses of recombinant plague vaccine at one of three dose levels (rF1 and rV recombinant antigen proteins).
Interventions
- BIOLOGICAL Alhydrogel
- BIOLOGICAL rF1 and rV protein antigens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00246467
The ClinicalTrials.gov registry entry for NCT00246467 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmAthene UK Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alhydrogel is the first listed.
NCT00246467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00246467 about?
NCT00246467 is a clinical study titled "One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)". One hundred and five subjects will be recruited into three groups. Each subject will receive two doses of recombinant plague vaccine at one of three dose levels (rF1 and rV recombinant antigen proteins).
What is the current status of trial NCT00246467?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 123 participants. The study started on 2005-10. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00246467?
The interventions under investigation include: Alhydrogel (BIOLOGICAL), rF1 and rV protein antigens (BIOLOGICAL).
Who is sponsoring clinical trial NCT00246467?
This trial is sponsored by PharmAthene UK Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.